治疗心力衰竭新药:vericiguat

A new drug in treating heart failure:vericiguat

vericiguat是一种可溶性鸟苷酸环化酶(sGC)激动剂,由默沙东和拜耳联合开发,于2021年1月被美国食品和药物管理局批准用于治疗伴有症状的射血分数小于45%的成人慢性心力衰竭患者。vericiguat可独立于内源性NO直接刺激sGC,也可以与内源性NO协同作用,双重机制刺激sGC产生大量c GMP,从而抑制心室重构、改善心肌功能。目前临床研究表明,与安慰剂相比,vericiguat可降低高危心力衰竭患者的心血管疾病死亡或心力衰竭住院(HFH)发生率。常见不良反应有低血压和贫血。

Vericiguat,a stimulator of soluble guanylate cyclase(sGC),was developed by Merck Sharp&Dohme and Bayer.It was approved for the treatment of symptomatic chronic heart failure with ejection fraction<45%in adults by the U.S.Food and Drug Administration in January,2021.Vericiguat stimulates sGC to generate cGMP,independently of and synergistically with NO,which inhibits the ventricular remodeling and improves cardiac function.Clinical trials showed that the incidence of death from cardiovascular causes or hospitalization for heart failure in patients with high-risk heart failure was lower among those who received vericiguat than among those who received placebo.In the clinical study,the most frequent vericiguat-related adverse reactions were hypotension and anaemia.